HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells

Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers. However, as with other targeted therapies, intrinsic or acquired resistance to HER2 inhibitors presents unresolved therapeutic problems for HER2-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Kang-Seo, Hong, Yong Sang, Choi, Junyoung, Yoon, Shinkyo, Kang, Jihoon, Kim, Deokhoon, Lee, Kang-Pa, Im, Hyeon-Su, Lee, Chang Hoon, Seo, Seyoung, Kim, Sang-We, Lee, Dae Ho, Park, Sook Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330940/
https://www.ncbi.nlm.nih.gov/pubmed/30591093
http://dx.doi.org/10.5483/BMBRep.2018.51.12.259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330940/
https://www.ncbi.nlm.nih.gov/pubmed/30591093
http://dx.doi.org/10.5483/BMBRep.2018.51.12.259

Ejemplares similares